Literature DB >> 10077306

Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study.

G T Harvey1, J Hughes, I G McKeith, R Briel, C Ballard, A Gholkar, P Scheltens, R H Perry, P Ince, J T O'Brien.   

Abstract

BACKGROUND: Temporal lobe atrophy on magnetic resonance imaging (MRI) has been suggested as a specific diagnostic marker for Alzheimer's disease (AD). No previous comparison with dementia with Lewy bodies (DLB) has been reported.
METHOD: T1-weighted MRI scans were performed on 11 subjects with AD (nine with NINCDS/ADRDA probable AD and two with neuropathologically proven AD) and nine subjects with DLB (four with probable DLB diagnosed by clinical criteria and five with neuropathologically proven DLB). Groups were matched for age, duration of illness and cognitive test score. Two raters, blind to diagnosis and neuropathological findings, measured the volumes of the frontal lobes, temporal lobes, hippocampi, parahippocampal gyri, amygdalae, and caudate nuclei using a computerized volumetric analysis system. Scans were also rated for medial temporal atrophy on a four-point scale by an experienced rater.
RESULTS: AD subjects had significantly smaller left temporal lobes and parahippocampal gyri than those with DLB. Medial temporal atrophy was present in 9/11 AD cases (82%) and absent in 6/9 (67%) of DLB cases. Two neuropathologically confirmed cases of DLB had severe medial temporal atrophy; both had concurrent AD-type pathology in the temporal lobe (Braak stage 4).
CONCLUSIONS: This pilot study supports the hypothesis that a greater burden of pathology centres on the temporal lobes in AD compared with DLB, except in DLB cases with concurrent Alzheimer pathology. A larger study is needed to confirm these findings and to determine whether MRI has a role in assisting with the clinical differentiation between DLB and AD.

Entities:  

Mesh:

Year:  1999        PMID: 10077306     DOI: 10.1017/s0033291798007806

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  6 in total

1.  Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra: A comparison with conventional voxel-based morphometry.

Authors:  R Takahashi; K Ishii; N Miyamoto; T Yoshikawa; K Shimada; S Ohkawa; T Kakigi; K Yokoyama
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-15       Impact factor: 3.825

Review 2.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

3.  Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies.

Authors:  Zuzana Nedelska; Tanis J Ferman; Bradley F Boeve; Scott A Przybelski; Timothy G Lesnick; Melissa E Murray; Jeffrey L Gunter; Matthew L Senjem; Prashanti Vemuri; Glenn E Smith; Yonas E Geda; Jonathan Graff-Radford; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Clifford R Jack; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2014-07-15       Impact factor: 4.673

Review 4.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

Review 5.  Tracking Alzheimer's disease.

Authors:  Paul M Thompson; Kiralee M Hayashi; Rebecca A Dutton; Ming-Chang Chiang; Alex D Leow; Elizabeth R Sowell; Greig De Zubicaray; James T Becker; Oscar L Lopez; Howard J Aizenstein; Arthur W Toga
Journal:  Ann N Y Acad Sci       Date:  2007-02       Impact factor: 5.691

6.  Rates of cerebral atrophy differ in different degenerative pathologies.

Authors:  Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs
Journal:  Brain       Date:  2007-03-08       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.